Onco-Summaries: Daily Oncology Updates at a Glance

13/05/2026

---

• FDA grants Fast Track to SUPLEXA, advancing Alloplex’s non-engineered immune cell therapy for MSI-H colorectal cancer

---

FDA grants Fast Track to SUPLEXA, advancing Alloplex’s non-engineered immune cell therapy for MSI-H colorectal cancer (Ref)

The FDA has granted Fast Track Designation to SUPLEXA for treating colorectal cancer patients with the MSI-H phenotype

Alloplex has submitted its US IND package for SUPLEXA in CRC-MSI-H and is advancing preparatory clinical activities

Return to Top